Safety remains the key metric for Cogent
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
Conjugates dominate human trial entries
ADCs newly into human trials include Lilly's PTK7 and two bispecifics.
M&A analysis: signs of life emerge
Some big deals in the second quarter have raised hopes that takeouts are back.
Dizal's US first; now what?
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
Regeneron enters the T-cell engager arena
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
FDA red and green lights: June 2025
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
Amgen and Zai Lab eye a gastric niche
Adverse events will be closely watched when full data are reported.
BeOne tries to repeat the inhibitor-degrader double
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
The month ahead: July’s upcoming events
Regeneron is facing two FDA decisions for its T-cell engagers.
BeOne also needs B7-H4 biomarkers
The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.
